Treatment preference and quality of life impact: Ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Authors

Teri J Mauch, University of Nebraska Medical Center
Michael R Chladek, Clinical Outcomes Solutions
Spero Cataland, Ohio State University
Shruti Chaturvedi, Johns Hopkins University
Bradley P Dixon, University of Colorado
Katherine Garlo, AstraZeneca Rare Disease
Christoph Gasteyger, AstraZeneca Rare Disease
Anuja Java, Washington University School of Medicine in St. Louis
Jorge Leguizamo, Northside Hospital Cancer Institute
Lucy Lloyd-Price, Clinical Outcomes Solutions
Tan P Pham, Clinical Outcomes Solutions
Tara Symonds, Clinical Outcomes Solutions
Ioannis Tomazos, AstraZeneca Rare Disease
Yan Wang, AstraZeneca Rare Disease

Journal

Journal of Comparative Effectiveness Research

Publication Date

9-1-2023

Volume

12

Issue

9

First Page

e230036

Document Type

Open Access Publication

DOI

10.57264/cer-2023-0036

Rights and Permissions

Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 Sep;12(9):e230036. doi: 10.57264/cer-2023-0036. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Mauch, Teri J; Chladek, Michael R; Cataland, Spero; Chaturvedi, Shruti; Dixon, Bradley P; Garlo, Katherine; Gasteyger, Christoph; Java, Anuja; Leguizamo, Jorge; Lloyd-Price, Lucy; Pham, Tan P; Symonds, Tara; Tomazos, Ioannis; and Wang, Yan, "Treatment preference and quality of life impact: Ravulizumab vs eculizumab for atypical hemolytic uremic syndrome." Journal of Comparative Effectiveness Research. 12, 9. e230036 (2023).
https://digitalcommons.wustl.edu/oa_4/2212

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.